The EU Commission sends a statement of objections to pharmaceutical companies over pay-for-delay agreements (Lundbeck)

On 25 July 2012, the European Commission announced that it had sent a formal Statement of Objections (“SO”) to Danish pharmaceutical company Lundbeck over its conclusion of so-called “pay-for-delay” agreements with four generic producers of citalopram, a antidepressant medicine. In its SO, the Commission alleges that Lundbeck concluded agreements with generic producers of citalopram to prevent the entry of generic versions of the medicine on the market, contrary to Article 101 TFEU. In theory, entry on the market of generic versions of citalopram should have been possible when some of

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Van Bael & Bellis (Brussels)

Citation

Peter L'Ecluse, The EU Commission sends a statement of objections to pharmaceutical companies over pay-for-delay agreements (Lundbeck), 25 juillet 2012, e-Competitions July 2012, Art. N° 58347

Visites 200

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues